Traitement des infections ostéo-articulaires bactériennes en dehors des infections à mycobactéries Document de travail proposé par le comité d'organisation (juillet 1990)

Choutet, P.; Desplaces, Nicole; Evrard, Jacques; Quinet, B.; Peyramond, D.; Lopitaux, R; Mamoudy, P.; Bègué, P; Dellamonica, P.

doi:10.1016/s0399-077x(05)80112-x

Cited by 11 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serious rifampicin‐induced hepatitis has been reported in patients treated for tuberculosis, but who usually received a combination of isoniazid, rifampicin, and pyrazinamide [23]. In fact, rifampicin‐induced hepatitis seems to be rare, and rifampicin might synergistically increase the risk of isoniazid or pyrazinamide‐induced hepatitis in patients treated for tuberculosis [14,24]. In our study, elevated ALT values were rare, never reached critical levels, and were not clinically relevant.…”

Section: Discussionmentioning

confidence: 52%

See 1 more Smart Citation

Lack of association between rifampicin plasma concentration and treatment‐related side effects in osteoarticular infections

Besnier

Giraudeau

Simonnard

et al. 2007

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

The aim of this study was to assess the frequency of gastrointestinal side effects (GSE) and hepatotoxicity in patients treated with rifampicin for an osteoarticular infection and to determine if there is an association between rifampicin plasma concentrations and side effects. Rifampicin plasma concentrations were prospectively measured before (trough concentration, C(0)) and 2 +/- 0.5 h (peak concentration, C(2)) after drug intake. The presence of GSE, the alanine transferase (ALT) value, and concomitantly administered medications were recorded on the day rifampicin concentrations were measured. C(0) and C(2) were compared for differences regarding the presence or absence of side effects. Multivariate analysis was performed, with associated medications being taken into account. Seventy C(0) and 57 C(2) values were measured in 46 adults after a median treatment of 8 days (range, 1-179). Wide inter-individual variability was observed for C(0) and C(2). Thirteen (28%) patients reported GSE at least once. When GSE occurred, C(0) (median, 1 mg L(-1); range, 0.1-9.9 mg L(-1)) and C(2) (median, 10.3 mg L(-1); range, 1.8-40.3 mg L(-1)) were similar to C(0) (median, 0.6 mg L(-1); range, 0.1-10.3 mg L(-1)) and C(2) (median, 10.9 mg L(-1); range, 2.9-29.0 mg L(-1)) without GSE. The ALT value was more than normal in only three patients (6.5%) after rifampicin treatment began. The patients received no different associated medications whether or not GSE were present. Multivariate analysis showed no association between rifampicin plasma concentrations and GSE. GSE occur frequently in patients receiving rifampicin for osteoarticular infection but without an association with rifampicin plasma concentrations. Thus, therapeutic drug monitoring of rifampicin is irrelevant in the management of GSE.

show abstract

Section: Discussionmentioning

confidence: 52%

“…However, rifampicin is perceived by clinicians as poorly tolerated when used to treat staphylococcal infections. Nausea, vomiting, and abdominal cramps could occur more frequently when 600 mg of rifampicin is administered twice daily, which is recommended for osteoarticular infections [14].…”

Section: Introductionmentioning

confidence: 99%

Lack of association between rifampicin plasma concentration and treatment‐related side effects in osteoarticular infections

Besnier

Giraudeau

Simonnard

et al. 2007

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Il peut être guidé par les circonstances étiologiques (porte d'entrée potentielle, terrain favorisant le développement de certains germes) [25], épidé-miologique en considérant la prééminence des staphylocoques en général [26], en fonction des antibiotiques déjà prescrits si tel est le cas, et en fonction de critères microbiologiques et pharmacologiques propre aux infections osseuses en général [27,28,29].…”

Section: Discussionunclassified

Spondylodiscites présumées infectieuses sans preuve bactériologique à propos de huit cas, comparaison des aspects cliniques, du pronostic et du traitement antibiotique avec les spondylodiscites à pyogènes documentées

Gillard

Boutoille

Varin

et al. 2005

Revue du Rhumatisme

View full text Add to dashboard Cite

“…The duration of antimicrobial treatment for bone and joint infections has not yet been standardized [59,60]. Studies suggest a treatment duration of six weeks, even in the event of orthopedic device infection [61,62].…”

Section: Infected Pressure Ulcer With Osteitismentioning

confidence: 99%

Management of established pressure ulcer infections in spinal cord injury patients

Dinh¹,

Bouchand²,

Duran³

et al. 2019

Médecine et Maladies Infectieuses

View full text Add to dashboard Cite

Traitement des infections ostéo-articulaires bactériennes en dehors des infections à mycobactéries Document de travail proposé par le comité d'organisation (juillet 1990)

Cited by 11 publications

References 0 publications

Lack of association between rifampicin plasma concentration and treatment‐related side effects in osteoarticular infections

Lack of association between rifampicin plasma concentration and treatment‐related side effects in osteoarticular infections

Spondylodiscites présumées infectieuses sans preuve bactériologique à propos de huit cas, comparaison des aspects cliniques, du pronostic et du traitement antibiotique avec les spondylodiscites à pyogènes documentées

Management of established pressure ulcer infections in spinal cord injury patients

Contact Info

Product

Resources

About